Cohort Innovation Day

Anny worked 28 years at MSD in clinical research and medical affairs, leading observational studies, early access programs, and academic partnerships. She helped launch the MSDAVENIR fund and served as VP of ARIIS. Now active with FIAC and Seintinelles, she also advises MSDAVENIR and INSERM Transfert.

Anny Tirel represents Seintinelles, a citizen community supporting cancer research, and chairs the FIAC Stakeholder Committee, which brings together patients, researchers, care centers, and public-private actors (INCa, HDH, ARIIS, France Biotech, major pharma companies).

Caroline Lafitte works at Sanofi R&D as Ecosystem & Scientific Innovation Lead in the Translational Medicine Unit. She has spent her entire career in R&D, holding various positions, mainly in Operational Development. She is a physiologist by training.

Sanofi is a biopharmaceutical company that innovates in R&D and leverages AI at scale to improve people’s lives and achieve long-term growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by a single goal: we pursue the miracles of science to improve people’s lives. This inspires us to drive progress and make a positive impact for our employees and the communities we serve, addressing the most pressing health, environmental, and societal challenges of our time.

Cécile Fouret is a trained pharmacist and a graduate of ESC Tours. She began her career at AFSSAPS (now ANSM) and later worked at PAREXEL. For over 20 years at Medtronic, she has held positions including Head of Market Access and Regulatory Affairs, Director of Clinical and Scientific Affairs, and Responsible Pharmacist for the establishment. As part of the Medicen Project Evaluation Committee, she also supports the development of innovative projects.

Medtronic is a global leader in healthcare technology, dedicated to alleviating pain, restoring health, and extending life through innovative medical devices and therapies. Founded in 1949, Medtronic employs over 95,000 people across 150 countries. Their solutions address more than 70 health conditions, treating approximately 74 million patients annually.
In fiscal year 2024, Medtronic achieved around $31 billion in revenue, investing $2.7 billion in R&D, leading to over 43,000 active patents and more than 190 ongoing clinical trials. Headquartered operationally in Minneapolis and legally in Dublin, Ireland, the company continues to pioneer life-changing technologies like pacemakers, insulin pumps, and neuromodulation devices.

Research projects focusing primarily on identifying risk factors for Alzheimer’s disease and age-related cognitive disorders, both at the individual and contextual levels.

Expertise in the design, management, and scientific production of large population-based cohort studies in France.

Numerous responsibilities in the evaluation of research and public health policies in France.

Grégoire Rey is a statistician and epidemiologist at Inserm. He initially focused on studying medical causes of death, particularly the links between mortality and summer temperatures, socio-economic status, and quality of care. As director of CépiDc (the French Centre for Epidemiology on Medical Causes of Death) from 2013 to 2022, he promoted the development of methods in biostatistics to improve data processing, artificial intelligence to speed up data production, and documentation and open data practices to enhance data reuse. He now leads the national research infrastructure France Cohortes.

France Cohortes is a national infrastructure dedicated to supporting public health cohort research. Backed by France’s Investment for the Future Program and led by Inserm and major academic partners, it provides a secure, sovereign platform for data collection, processing, and reuse. It also offers expert guidance on regulatory, technical, and communication aspects.
France Cohortes promotes open science and FAIR data principles to enhance disease prevention and healthcare through long-term data valorization.

Jérémie Rudant, Public Health physician with a PhD in epidemiology, spent 10 years in academic and public health roles, including at Inserm and CNAM, focusing on cancer and health data research. He joined Pfizer in 2019 as Real World Evidence Medical Manager, leading studies on unmet medical needs and post-marketing evaluation of Pfizer treatments, especially in rare diseases and immunology.

Pfizer is a global biopharmaceutical company dedicated to discovering and delivering innovative medicines and vaccines that improve lives. Founded in 1849 and headquartered in New York City, Pfizer employs over 80,000 people worldwide. The company focuses on key therapeutic areas such as oncology, immuno-inflammation, vaccines, and cardiovascular and metabolic diseases. With a strong commitment to quality, safety, and access, Pfizer works closely with healthcare providers, governments, and communities around the world to advance health solutions and make a lasting impact.

Veterinarian and immunologist, Marc Bonneville is Vice-President of Scientific and Medical Affairs at Institut Mérieux. Former INSERM center director and CNRS scientist, he has led research in cellular immunology and co-founded Innate Pharma. Author of 200+ publications and holder of 8 patents, he has received numerous scientific awards.

Ariis is a public-private alliance fostering collaboration between healthcare industry players and academic research institutions, promoting innovation and accelerating partnerships in health and life sciences.

Medical Doctor and PhD in Epidemiology, he began at INSERM on HIV cohort studies before founding a clinical research company and serving as Medical Director at Cegedim. He joined Institut Curie in 2010, then led Unicancer’s ESME real-world data program from 2014. After roles at CT.RS and as advisor at Unicancer, he became Scientific Director of Unicancer’s Data Department in 2023, driving research partnerships and innovation in health data reuse.

Unicancer is the only French hospital network fully dedicated to cancer care, uniting 18 CLCCs and 2 affiliates across 22 sites, treating nearly 550,000 patients annually. A leader in real-world data, it runs major platforms like ESME, ODH, and CANTO, and integrates SNDS data via the HARMONIE warehouse to support coordinated cancer care. Unicancer is also Europe’s top academic sponsor of oncology trials, promoting over 100 studies and contributing to one-third of French oncology publications.

Professor Pierre-Marie Preux is Professor of Epidemiology, Health Economics, and Prevention at the University of Limoges and heads the EpiMaCT research unit. Initially trained as a neurologist and with a degree in tropical medicine, he then turned his attention to public health. He is heavily involved in research into the epidemiology of chronic diseases in tropical areas. Former Vice-President of Research at the University of Limoges (2016–2020), he chairs the epidemiology sub-section of the National Council of Universities (CNU) and is head of the neuroepidemiology group of the World Federation of Neurology. He also leads the INSPIRE-UAC project (Partnerships with African Higher Education – PEA) in collaboration with Benin.

EpiMaCT (Epidemiology of Chronic Diseases in Tropical Areas) is a research unit accredited by Inserm and IRD, under the supervision of the University of Limoges and Limoges University Hospital. Specializing in the study of chronic diseases in countries in the Global South (particularly sub-Saharan Africa and Southeast Asia), this international organization develops approaches in public health, epidemiology, and prevention. It has 96 members, including 33 doctoral students enrolled in 2024-2025.